AZD7789 is named as a drug or biological intervention in 2 clinical trials in our USA and China trial registers, none of which are currently recruiting. The lead sponsor is AstraZeneca. Registered phases: Phase 1 and Phase 1/2. Conditions studied include Advanced or Metastatic NSCLC; Carcinoma, Non-Small-Cell Lung; Gastric Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer (ClinicalTrials.gov ↗) Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer |
Phase 1/2 | Active, closed |
| NCT04612751 | Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (ClinicalTrials.gov ↗) Advanced or Metastatic NSCLC |
Phase 1 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced or Metastatic NSCLC | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Gastric Cancer | 1 |
| Gastroesophageal Junction Cancer | 1 |
| Lead sponsor | Trials |
|---|---|
| AstraZeneca | 2 |
| Register | AZD7789 trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how AZD7789 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists AZD7789 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.